Lung Non-Squamous Non-Small Cell Carcinoma

A 65-year old female diagnosed with lung adenocarcinoma revealed several brain lesions, the largest measuring 1.8 x 1.5 x 1.9 cm. COBAS EGFR mutation test was run and revealed EGFR exon 19 deletion mu… (full text at CIViC)

PMID 36188633 · Wilgucki et al., 2022 · Open in CIViC

In retrospective analysis of trials, afatinib conferred limited clinical benefit to patients with EGFR exon 20 insertion mutations (N=23). Only 2 patients had objective responses.

PMID 26051236 · Yang et al., 2015 · Open in CIViC

A retrospective study showed that out of 11 patients with stage IV lung adenocarcinoma treated with erlotinib who carried in-frame exon 20 insertion variant, only 3 patients showed objective response … (full text at CIViC)

PMID 26096453 · Naidoo et al., 2015 · Open in CIViC

A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 del… (full text at CIViC)

PMID 21969500 · Brugger et al., 2011 · Open in CIViC

In a meta-analysis of 7 clinical trials of erlotinib (some vs placebo or other treatment), 10/24 patients with Exon 18 mutations harbored a G719 variant. These variants were associated with improved p… (full text at CIViC)

PMID 26773740 · Klughammer et al., 2016 · Open in CIViC

In a retrospective study of 46, Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR G719A mutation was associated with resistance to erlotinib treatment. The patient survived 9.… (full text at CIViC)

PMID 27032107 · De Grève et al., 2016 · Open in CIViC

A 60-year old man (smoker: 300 pack-years) presented with lung adenocarcinoma measuring 3.0 x 2.3 cm and multiple lymph node metastases. Next-generation sequencing revealed a EGFR G719A (abundance 5.0… (full text at CIViC)

PMID 30922580 · Zeng et al., 2019 · Open in CIViC

In an advanced lung adenocarcinoma patient harboring EGFR G719S mutation, EGFR G719S was reported to be sensitive to erlotinib treatment. The patient was initially treated with standard chemotherapy, … (full text at CIViC)

PMID 21841502 · De Pas et al., 2011 · Open in CIViC

A 58-year-old male with stage IVB lung adenocarcinoma presented with respiratory symptoms and widespread metastases. NGS revealed EGFR-GNAT3 fusion (EGFR exons 1–24 to GNAT3 exon 8; 76.3% abundance) a… (full text at CIViC)

PMID 38595815 · Wang et al., 2024 · Open in CIViC

A 61 year old male never smoker with EGFR H773_V774insNPH mutant lung adenocarcinoma was treated with fourth line erlotinib and had progressive disease as best response, progression free survival of 1… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation K757R from the MERIT study. Progression-free (250 days) and overall (4… (full text at CIViC)

PMID 26773740 · Klughammer et al., 2016 · Open in CIViC

A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. A set of osimertinib resistant tumours were treated with 25mg/kg osimertinib and 2… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. Mice were treated with either daily 5mg/kg, followed by 25mg/kg after tumour recur… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

A 62 year old patient with 4 pack-year smoking history with back and flank pain was found to have metastatic lung adenocarcinoma by CT and MRI. Targeted NGS sequencing discovered an EGFR L858R mutatio… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

A 62 year old patient with 4 pack-year smoking history with back and flank pain was found to have metastatic lung adenocarcinoma by CT and MRI. Targeted NGS sequencing discovered an EGFR L858R mutatio… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

Preclinical models of osimertinib-resistant EGFR mutants were treated with erlotinib or afatinib. Treatment with erlotinib suppressed phosphorylation of EGFR L858R+C797S but did not decrease phosphory… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. Mice were treated with either daily 5mg/kg, followed by 25mg/kg after tumour recur… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

In a retrospective study of 46 Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR L747_P753insS mutation was associated with resistance to erlotinib treatment. The patient surv… (full text at CIViC)

PMID 27032107 · De Grève et al., 2016 · Open in CIViC

EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib in a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma). One patient … (full text at CIViC)

PMID 15329413 · Pao et al., 2004 · Open in CIViC

A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R+T790M transgene. Twenty of 49 mice treated with osimertinib developed treatment-resistant tum… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

Two patients with advanced lung adenocarcinoma harboring the EGFR L833V/H835L compound mutation received first-line furmonertinib (80 mg once daily), and both achieved partial responses according to R… (full text at CIViC)

PMID 40963567 · Wang et al., 2025 · Open in CIViC

In this preclinical study, expression of EGFR L858R in Ba/F3 cells induced interleukin-3-independent proliferation, demonstrating ligand-independent cellular transformation. EGFR L858R was constitutiv… (full text at CIViC)

PMID 16204070 · Jiang et al., 2005 · Open in CIViC

A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months… (full text at CIViC)

PMID 23816960 · Sequist et al., 2013 · Open in CIViC

A 76-year old woman (non-smoker) presented with stage IVB ling adenocarcinoma. Genetic testing was positive for EGFR L858R and T790M and osimertinib was given. Partial response was noted until progres… (full text at CIViC)

PMID 36313664 · Takamori et al., 2022 · Open in CIViC

A 67 year old female with stage IIIA lung adenocarcinoma had right lobectomy followed by 4 cycles adjuvant chemotherapy with pemetrexed and cisplatin. Next generation sequencing (NGS) found EGFR L858R… (full text at CIViC)

PMID 35004270 · Wang et al., 2021 · Open in CIViC

The phase 3 (EURTAC) study consisted of of 173 non-small cell lung cancer patients who had not had prior chemotherapy for metastatic disease (although adjuvant or neoadjuvant chemotherapy was permitte… (full text at CIViC)

PMID 22285168 · Rosell et al., 2012 · Open in CIViC

In a patient with metastatic adenocarcinoma of the lung harboring EGFR L861R mutation, MET D1028H and EGFR amplification, EGFR L861R was associated with acquired resistance to crizotinib monotherapy. … (full text at CIViC)

PMID 26845121 · Benderra et al., 2016 · Open in CIViC

A 65-year-old female with lung adenocarcinoma underwent NGS testing, revealing an EGFR-MACF1 fusion at the RNA level (mutation abundance: 17%) and EGFR amplification (copy number: 24.15). The fusion i… (full text at CIViC)

PMID 38595815 · Wang et al., 2024 · Open in CIViC

In a study of 1036 patients with lung adenocarcinomas, patients with EGFR mutations (n=275) showed better prognosis (OS: 34 months versus 23 months; HR=0.6; P<0.001).

PMID 22810899 · Johnson et al., 2013 · Open in CIViC

Analysis was performed on the placebo group (n=451) of the Phase III study SATURN using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease … (full text at CIViC)

PMID 21969500 · Brugger et al., 2011 · Open in CIViC

A transposon mutagenesis screen for resistance to a second-generation TKI afatinib was performed in EGFR-TKI sensitive PC9 lung adenocarcinoma cell line that harbours exon 19 EGFR deletion. YES1 was f… (full text at CIViC)

PMID 29875142 · Fan et al., 2018 · Open in CIViC

In a retrospective study of 46 Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR N771insVH mutation was associated with resistance to erlotinib treatment. The patient survived… (full text at CIViC)

PMID 27032107 · De Grève et al., 2016 · Open in CIViC

A 57 year old male 10 packyear former smoker with lung adenocarcinoma with EGFR P772_V774insPHV mutation was given erlotinib as first line treatment, and had progressive disease as best response with … (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

A metastatic lung adenocarcinoma (bone and brain) was diagnosed in a 42-year-old woman (patient 3). The primary adenocarcinoma was found in left lower lobe (LLL). Her initial treatment with whole-brai… (full text at CIViC)

PMID 27102076 · Konduri et al., 2016 · Open in CIViC

A 62 year-old female never smoker diagnosed of lung adenocarcinoma that was negative for EGFR and ALK alterations (EGFR hotspot tissue NGS) was treated with carboplatin/ pemetrexed/ bevacizumab (x 6 c… (full text at CIViC)

PMID 29472054 · Raez et al., 2018 · Open in CIViC